We are live on ! Find out more
TRCT

Tower Research Capital (TRC) Portfolio holdings

AUM $4.08B
1-Year Est. Return 58.77%
This Fund
S&P 500
This Quarter Est. Return
+7.58%
1 Year Est. Return
+58.77%
3 Year Est. Return
+143.94%
5 Year Est. Return
+167.17%
10 Year Est. Return
+536.06%
AUM
$2.41B
AUM Growth
-$3.75B
Cap. Flow
-$4.09B
Cap. Flow %
-169.35%
Top 10 Hldgs %
31.78%
Holding
6,989
New
537
Increased
1,703
Reduced
3,620
Closed
686

Sector Composition

Rank Sector Weight
1 Technology 21.73%
2 Healthcare 7.71%
3 Consumer Discretionary 6.84%
4 Financials 6.55%
5 Industrials 4.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BH.A icon
3576
Biglari Holdings Class A
BH.A
$1.2B
$13K ﹤0.01%
19
-9
-32% -$6.06K
BHE icon
3577
Benchmark Electronics
BHE
$2.94B
$13K ﹤0.01%
483
-7,876
-94% -$218K
BKKT icon
3578
Bakkt Inc
BKKT
$342M
$13K ﹤0.01%
437
+306
+234% +$14.3K
BOXL icon
3579
Boxlight
BOXL
$4.64M
$13K ﹤0.01%
29
+19
+190% +$12.1K
BPRN icon
3580
Princeton Bancorp
BPRN
$296M
$13K ﹤0.01%
400
+242
+153% +$7.56K
BSV icon
3581
Vanguard Short-Term Bond ETF
BSV
$45.7B
$13K ﹤0.01%
177
+132
+293% +$9.9K
CADL icon
3582
Candel Therapeutics
CADL
$859M
$13K ﹤0.01%
7,214
+3,077
+74% +$6.09K
CAMT icon
3583
Camtek
CAMT
$7.72B
$13K ﹤0.01%
608
+467
+331% +$10.8K
CIA icon
3584
Citizens
CIA
$201M
$13K ﹤0.01%
6,275
-2,483
-28% -$6.92K
CLDX icon
3585
Celldex Therapeutics
CLDX
$3.29B
$13K ﹤0.01%
309
-6,496
-95% -$232K
CLOV icon
3586
Clover Health Investments
CLOV
$2.44B
$13K ﹤0.01%
13,497
-29,372
-69% -$39.2K
CLRB icon
3587
Cellectar Biosciences
CLRB
$20.8M
$13K ﹤0.01%
260
+210
+420% +$12.6K
CODI icon
3588
Compass Diversified
CODI
$956M
$13K ﹤0.01%
715
-11,136
-94% -$209K
CYRX icon
3589
CryoPort
CYRX
$772M
$13K ﹤0.01%
742
-3,219
-81% -$67.8K
CZNC icon
3590
Citizens & Northern Corp
CZNC
$466M
$13K ﹤0.01%
585
-27
-4% -$647
DARE icon
3591
Dare Bioscience
DARE
$13.9M
$13K ﹤0.01%
1,264
-815
-39% -$9.11K
DHX icon
3592
DHI Group
DHX
$171M
$13K ﹤0.01%
2,510
-2,347
-48% -$13K
DTIL icon
3593
Precision BioSciences
DTIL
$205M
$13K ﹤0.01%
355
-500
-58% -$19.8K
DX
3594
Dynex Capital
DX
$3.24B
$13K ﹤0.01%
1,018
-8,326
-89% -$103K
EAF icon
3595
GrafTech
EAF
$199M
$13K ﹤0.01%
265
-1,223
-82% -$59.4K
EAT icon
3596
Brinker International
EAT
$10.2B
$13K ﹤0.01%
405
-3,798
-90% -$119K
EGAN icon
3597
eGain
EGAN
$206M
$13K ﹤0.01%
1,401
-11,395
-89% -$93.8K
EWL icon
3598
iShares MSCI Switzerland ETF
EWL
$2.21B
$13K ﹤0.01%
307
+28
+10% +$1.14K
FBRT
3599
Franklin BSP Realty Trust
FBRT
$670M
$13K ﹤0.01%
1,027
-6,981
-87% -$93.4K
FMX icon
3600
Fomento Económico Mexicano
FMX
$40.3B
$13K ﹤0.01%
+172
New +$12.7K

Similar funds

Tower Research Capital (TRC)'s Q4 2022 Portfolio in Review

As of Q4 2022, Tower Research Capital (TRC) held 6,989 positions worth $2.41B, down 61% from $6.16B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Tower Research Capital (TRC) withdrew a net $4.09B in Q4 2022, closing 686 positions and reducing 3,620 holdings. Its most notable exit was Vanguard Russell 2000 Value ETF, an estimated $4.46M position sold in full.

By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Tower Research Capital (TRC) opened a new position in iShares Semiconductor ETF worth $9.33M.

  • Tower Research Capital (TRC)'s largest Q4 2022 buy was iShares Semiconductor ETF: 80,454 shares worth $9.33M.
  • Tower Research Capital (TRC) added most to iShares Russell 2000 ETF in Q4 2022, an estimated $145M increase.
  • Tower Research Capital (TRC)'s biggest Q4 2022 reduction was Apple, cutting an estimated $322M.
  • Tower Research Capital (TRC) fully exited Vanguard Russell 2000 Value ETF in Q4 2022, selling an estimated $4.46M.
  • Tower Research Capital (TRC)'s ten largest holdings make up 32% of its $2.41B portfolio in Q4 2022.
  • Tower Research Capital (TRC) opened 537 new positions and closed 686 in Q4 2022.
  • Tower Research Capital (TRC)'s portfolio value fell 61% quarter-over-quarter to $2.41B.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.